CA-CONFLUENT
Confluent, Inc. , the platform to set data in motion, today announced Confluent for Kubernetes , the first platform purpose-built to bring cloud-native capabilities to data streams in private infrastructures. To make it easier and faster to harness the value of data in motion across an entire organization, Confluent drew on its expertise managing thousands of Apache Kafka® clusters in Confluent Cloud to offer the same cloud-native experience for on-premises environments. These cloud-native capabilities are key to running modern data platforms and are now available wherever an organization’s applications and data reside. Within minutes, it’s now possible to build a private cloud Kafka service that powers applications that are increasingly critical to how organizations thrive.
To win in today’s global economy, organizations must deliver exceptional customer experiences and data-driven, backend operations. This requires the ability to react, respond, and adapt to a continuous, ever-changing flow of data from across an organization in real time. This has driven the rapid rise of Kafka as a key enabler to helping companies cut across silos and process the flow of business events as they happen. However, given the high level of technical complexity, need for constant monitoring, and time-consuming custom tooling, self-managing Kafka is difficult and often takes large teams of specialized professionals. These challenges can result in costly project delays and inefficient resource investments, holding organizations back as they compete to innovate and win in a digital-first world.
“To compete in the digital realm, organizations need to quickly deliver personalized customer experiences and real-time operations, which are only possible with access to data from all environments and cloud-native advantages,” said Ganesh Srinivasan, Chief Product and Engineering Officer, Confluent. “For organizations that need to operate on premises, we’re bringing the benefits of cloud computing to their private infrastructure with Confluent for Kubernetes. Now, any company can build a private cloud service to move data across their business regardless of its environment.”
Confluent for Kubernetes – Bringing Benefits From the Leading Data in Motion Cloud Platform to On-Premises Environments
With the launch of Confluent for Kubernetes, Confluent brings together the cloud-native advantages learned from Confluent Cloud with the control and customization from self-managing their private infrastructure in on-premises environments. So whether an organization is transitioning to the cloud or needs to keep workloads on premises, they can take full advantage of Confluent for Kubernetes’ cloud-native capabilities, including a declarative API to deploy and operate Confluent. The platform also makes moving applications to the public cloud easier by seamlessly migrating workloads to wherever your business needs them with the ability to connect and share data with Confluent Cloud. By reimagining what is possible for private infrastructure with the capabilities of modern cloud computing, it is easier than ever for organizations to build and manage a private cloud Kafka service for moving data across a business.
- Enhanced reliability – As a cloud-native system, Confluent for Kubernetes intelligently detects if a process fails and will automatically restart processes or reschedule as necessary. Automated rack awareness spreads replicas of a partition across different racks, improving the availability of your brokers and limiting the risk of data loss. With automated reliability, organizations can minimize the risk of business disruption, reduce downtime costs, and limit data loss.
- Automated elasticity – Meet changing business demands with the ability to scale up using API-driven operations. The platform will automatically generate configurations, schedule and run new broker processes, and ensure data is balanced across brokers so that clusters can be efficiently utilized. With the ability to spin up and down Confluent clusters, organizations can control infrastructure costs while quickly scaling to meet their business needs.
- Simplified infrastructure management – A core concept of the cloud-native paradigm is the ability to focus on higher value activities that create business value rather than performing complex sequences of low-level infrastructure-related operations. Confluent for Kubernetes extends the Kubernetes API, enabling organizations to define the desired high-level state of clusters rather than manage all the low-level details. This infrastructure-as-code approach reduces operational burden and achieves a faster time to value, while enhancing security with standards that can be easily and consistently deployed across an organization.
Kafka Summit Europe 2021
Tune into Confluent Co-founder and CEO Jay Kreps’ keynote at Kafka Summit Europe on May 12 at 8:00 a.m. GMT to learn more about today’s news. Register now: https://kafkasummit.io/
For a deep dive into Confluent for Kubernetes, don’t miss this Kafka Summit Europe lightning talk happening today at 1 p.m. GMT: https://www.kafka-summit.org/sessions/gitops-for-kafka-with-confluent-for-kubernetes
Additional Resources
- For more details on how Confluent for Kubernetes works, check out our blog: https://www.confluent.io/blog/confluent-for-kubernetes-offers-cloud-native-kafka-automation/
- See how Confluent is helping its customers transform their businesses: https://www.confluent.io/customers/
- Learn more about Confluent: https://www.confluent.io/
- Join Confluent and apply for one of its open positions: https://www.confluent.io/careers/
About Confluent
Confluent is pioneering a fundamentally new category of data infrastructure focused on data in motion. Confluent’s cloud-native offering is the foundational platform for data in motion – designed to be the intelligent connective tissue enabling real-time data, from multiple sources, to constantly stream across the organization. With Confluent, organizations can meet the new business imperative of delivering rich, digital front-end customer experiences and transitioning to sophisticated, real-time, software-driven backend operations. To learn more, please visit www.confluent.io .
The preceding outlines our general product direction and is not a commitment to deliver any material, code, or functionality. The development, release, timing, and pricing of any features or functionality described may change. Customers should make their purchase decisions based upon services, features, and functions that are currently available. Confluent and associated marks are trademarks or registered trademarks of Confluent, Inc.
Apache® and Apache Kafka® are either registered trademarks or trademarks of the Apache Software Foundation in the United States and/or other countries. No endorsement by the Apache Software Foundation is implied by the use of these marks. All other trademarks are the property of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210512005181/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant Group Unveils China’s First Multimodal AI Assistant with Code-Driven Outputs18.11.2025 09:05:00 CET | Press release
Ant Group today launched LingGuang, a next-generation multimodal AI assistant and the first of its kind in China that interacts with users through code-driven outputs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251117438567/en/ Equipped with the capability to understand and produce language, image, voice and data, LingGuang delivers precise, structured responses to complex queries through 3D models, audio clips, charts, animations, interactive maps, and even immediately generated applications, in addition to traditional text-based conversation. Designed around three key features, LingGuang aims to make complex knowledge simpler and more intuitive, transforming how users access information and interact with AI tools. Fast Research: LingGuang responds to user questions or keywords with dynamic, multimodal content, making research on any topic clearer and more engaging. Its 3D digital modeling capability transcends traditio
SkySparc Appoints Oliver Bussmann as Chairman of the Board18.11.2025 09:00:00 CET | Press release
Appointment of industry veteran follows majority growth investment from Bregal Milestone SkySparc, a trusted global provider of digital transformation solutions for treasury and finance organizations, today announced the appointment of Oliver Bussmann as Chairman of the Board, following the closing of a majority growth investment from Bregal Milestone, a leading European software private equity firm. As former Global CIO at UBS and SAP, Bussmann has a proven track record of scaling B2B software and services across the Office of the CFO, Financial Services, RegTech, and WealthTech. Throughout his career, he has guided organizations through complex SaaS transitions, strategic M&A, and go-to-market acceleration – delivering multiple successful exits and sustained enterprise growth. Bussmann will help steer SkySparc’s technology and value-creation agenda, as Chairman, leveraging his network across financial services and technology to accelerate innovation, expand AI adoption, and drive lon
European Commission Grants Approval of Remsima™ IV Liquid Formulation, World’s First Liquid Formulation of IV Infliximab18.11.2025 08:23:00 CET | Press release
Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab has been approved by the European Commission (EC) for all previously approved indications for Remsima™ IV powder formulation1The approval is based on the comparability data between infliximab powder formulation and the liquid formulation2The new liquid formulation of infliximab, available in 100 mg and a newly introduced 350 mg presentation, eliminates the need for reconstitution and cuts drug preparation time by 51%, lowering preparation costs by 20%1,3Projected annual cost savings across seven European countries could reach up to €2.6 million, alongside significant improvements to workflow efficiency3 Celltrion, Inc. today announced that the European Commission (EC) has granted marketing authorization for Remsima™ IV (intravenous) liquid formulation, the world’s first liquid formulation of IV infliximab. Approved in 100 mg and 350 mg vials, the formulation is designed to streamline inf
Swiss-Based Debiopharm Seeks to Boost Innovation in Japanese Cancer Research Through the New "Ideal Japan” Program18.11.2025 08:00:00 CET | Press release
After 20 years of the prestigious JCA (Japanese Cancer Association) Mauvernay Award in Japan, Debiopharm is now transitioning its longstanding support for Japanese research to the new IDEAL Japan initiativeThe “Innovation Debiopharm Academia Life Science” (IDEAL) program is designed to financially and scientifically support academic research with the goal of accelerating the translation of innovation into novel therapies for patientsThe first IDEAL Japan agreement was signed with the National Cancer Center Japan Research Institute Laboratory of Genome Stability Maintenance to advance research in early-stage colon cancer Debiopharm (www.debiopharm.com), a Swiss biopharmaceutical company aiming to cure cancer and infectious diseases, is pleased to announce today the launch of the new IDEAL Japan initiative. This program was initiated to provide financial support to Japanese academic researchers in order to facilitate the transformation of academic innovation into novel therapeutic approa
Avanzanite Bioscience Secures €32M Series A Investment from MVM Partners18.11.2025 07:00:00 CET | Press release
MVM Partners joins as Avanzanite’s first institutional investor. Funding will scale Avanzanite’s existing infrastructure in all 32 countries in Europe, propel current launches, and support further product alliances and acquisitions. In just 3 years, Avanzanite has entered 3 strategic alliances and actively launched 3 rare disease medicines. Avanzanite’s Q3 2025 revenue tripled year-on-year and climbed over 20% quarter-on-quarter. Avanzanite is a unique, fully integrated partner for biotech and pharma innovators seeking to market and distribute their rare disease medicines in Europe. A new pan-European standard is being set for orphan medicine launches and patient access, with no one left behind. Avanzanite Bioscience B.V. (Avanzanite), a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today announced a €32 million Series A growth investment from MVM Partners (MVM), a leading global life-science private equity firm. This press release
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
